Keyphrases
Risk Factors
100%
Clinical Significance
100%
Lymphopenia
100%
Dimethyl Fumarate
100%
Factor Significance
100%
Multiple Sclerosis
37%
Lymphocytes
25%
Natalizumab
25%
Retrospective Cohort Study
12%
Clinical Response
12%
Older Patients
12%
Moderate to Severe
12%
Progressive multifocal Leukoencephalopathy
12%
Old Age
12%
Academic Medical Centers
12%
Multiple Sclerosis Treatment
12%
Disease-modifying Therapy
12%
Absolute Lymphocyte Count
12%
March 2013
12%
Drug Safety
12%
Grade 23
12%
Fumarate
12%
Real-world Population
12%
Drug Failure
12%
Infection Awareness
12%
Medicine and Dentistry
Clinical Significance
100%
Lymphocytopenia
100%
Fumaric Acid Dimethyl Ester
100%
Multiple Sclerosis
50%
Lymphocyte
37%
Natalizumab
25%
Biological Marker
12%
Infection
12%
Retrospective Cohort Study
12%
Progressive Multifocal Leukoencephalopathy
12%
Awareness
12%
Disease Modifying Therapy
12%
Drug Safety
12%
Alertness
12%
Fumaric Acid
12%